Biotie Buys Newron In Pain Deal; Price Brings Little Relief
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotie's acquisition of pain-focused Newron for €38 million upfront reflects the trouble Newron was in - and the riskiness of the field.